Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ATM |
| Variant | E2039K |
| Impact List | missense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | ATM E2039K lies within the FAT domain of the Atm protein (UniProt.org). E2039K retains protein stability but results in decreased phosphorylation of Atm downstream targets in response to irradiation in culture (PMID: 19431188), and therefore, is predicted to lead to a loss of Atm protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
ATM mutant ATM inact mut ATM E2039K |
| Transcript | NM_000051.4 |
| gDNA | chr11:g.108316030G>A |
| cDNA | c.6115G>A |
| Protein | p.E2039K |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_005271562 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_047426977.1 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542842.3 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| NM_001351834.2 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542840 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542840.4 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| NM_000051 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542843 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542842 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017790 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| NM_000051.4 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017790.2 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_005271561 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_006718843.5 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_047426978.1 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017790.3 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_047426976.1 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542843.2 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017791.1 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_006718843 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_006718843.4 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017789 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542842.4 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_047426975.1 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542840.3 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_005271562.6 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| NM_000051.3 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| NM_001351834.1 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017789.2 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_047426979.1 | chr11:g.108317454G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_005271562.5 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_017017791 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| XM_011542843.3 | chr11:g.108316030G>A | c.6115G>A | p.E2039K | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM E2039K | prostate cancer | sensitive | Olaparib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) improved progression-free survival (7.4 vs 3.6 mo, HR 0.34, p<0.001), objective response rate (33% vs 2%, OR 20.86, p<0.001), and median overall survival (18.5 vs 15.1 mo, HR 0.64, p=0.02) over control in metastatic prostate cancer patients harboring inactivating BRCA/ATM mutations as detected by approved assays, including ATM E2039K, HR was 1.04 in ATM-mutant group (PMID: 32343890; NCT02987543). | 32343890 detail... detail... |
| ATM E2039K | prostate cancer | sensitive | Enzalutamide + Talazoparib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM E2039K (PMID: 42223064; NCT04821622). | detail... 42223064 detail... |